Waldenström Macroglobulinemia

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Anal Cancer

Colorectal Cancer

Esophageal Cancer

Gallbladder Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Uterine Cancer

Vulvar Cancer

Gynecologic Cancer

Head & Neck Cancer

Immunotherapy

Acute Myeloid Leukemia

Leukemia

Mesothelioma

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Small Lymphocytic Lymphoma (SLL)

Lymphoma

Myeloma

Cancer of Unknown Primary

Carcinoid Cancer

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Melanoma

Skin Cancer

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

The brain cancer condition center is a comprehensive resource for cancer news & oncologist insights on brain cancer. Read more about cancer at CURE.

Brain Cancer | Oncology & Cancer News | Tumor | CURE

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

About

Advertise / Support

Contact

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

Tumor

CURE’s brain cancer page features the latest cancer news and updates on brain cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in brain cancer.

After a car accident, and experiencing what he thought was a stroke, Matt Newman was diagnosed with brain cancer at the age of 39 — an experience he found strength and courage in.

With a wife and three children at home, as well as a cancer partner in his father-in-law facing his own pancreatic cancer diagnosis, Matt immediately went into fight mode. He utilized fitness and exercise to get through his craniotomy recovery, and went on to write “Starting At The Finish Line,” which tells his personal story.

“I’ve earned my legacy and cancer had nothing to do with it,” he says.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.

Earning Your Legacy: Cancer Has Nothing To Do With It

Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue; however, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.

 Talks Cancer, founder and CEO of Savor Health, Susan Bratton discussed the importance of nutrition for patients and caregivers before, during and after treatment.

For more information, visit savorhealth.com, and to read some of the organization’s recipes, visit our Spring issue of 

In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.

Addressing Nutritional Needs in Cancer

After receiving a stage 4 neuroblastoma diagnosis at 15 months old, Candace Stevens beat the odds, and has used her experience to shape her career choice today.

Stevens was treated at St. Jude, and now participates in the institution’s LIFE program — research that brings long-term childhood cancer survivors back to St. Jude for regular health screenings throughout their adult lives. The findings from this research are helping survivors learn more about their individual health needs and also providing researchers with novel insights into the late effects of cancer therapy.

In this week’s episode, we spoke with Candace about growing up as a cancer survivor, why programs like St. Jude LIFE are helping other children moving forward, and why everyone should keep believing in miracles.

In this week’s episode of the CURE Talks Cancer podcast, we spoke with a childhood cancer survivor about her journey with stage 4 neuroblastoma, and also about taking part in the St. Jude LIFE research program.

Believing Miracles Can Happen

We’re wrapping up Childhood Cancer Awareness Month by talking to Micah Bernstein, a 7-year-old, three-time survivor of neuroblastoma, and her father, Jeff. 

Micah and Jeff discussed their experiences with the disease, as well as Micah’s participation in clinical trials, being a “tester for the drugs,” as she put it. Now that Micah has no evidence of disease (NED), she hopes that she can inspire other children who face a cancer diagnosis, and one day hopes to become a doctor.

Micah Bernstein is only 7 years old and has already fought cancer three times. Now, she hopes to be an inspiration to other children.

Words of Wisdom from a 7-Year-Old Cancer Survivor

Patients with glioblastoma experienced tumor control after complete in-situ vaccination and anti-PD-1 immunotherapy, researchers have reported.

Optune Plus Temodar and Keytruda May Result in Brain Tumor Control

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.

The Decision to Irradiate or Not to Irradiate My Daughter’s Brain Tumor

A colleague wrote about a dedicated oncology nurse who excels in patient care, demonstrates exceptional clinical skills and consistently goes above and beyond to improve patient outcomes.

A Great Display of Healing in Cancer Care

A phase 2 clinical trial of a new brain cancer treatment is underway.

First Patients Dosed in Phase 2 Trial of Ropidoxuridine for Glioblastoma

The FDA has accepted a new drug application for the glioma-imaging agent Pixclara, with a decision expected next year.

FDA Accepts New Drug Application for Pixclara for Glioma Imaging

SurVaxM, which is being study in gliobastoma, targets a certain protein that is found on the brain cancer cells. 

An Expert Breakdown of SurVaxM, the Novel Brain Cancer Vaccine

A novel cancer vaccine, SurVaxM, is being studied for the treatment of patients with newly diagnosed glioblastoma. A trial of the drug is currently fully enrolled, and results can be expected around this time next year, according to Dr. Manmeet S. Ahluwalia.

Ahluwalia is the chief scientific officer and chief of medical oncology and deputy director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. He recently sat down with CURE® at the 2024 

American Society of Clinical Oncology Annual Meeting

FDA Grants Fast Track Designation to SurVaxM for Newly Diagnosed Glioblastoma

Ahluwalia explained that SurVaxM targets the survivin protein, which is found on gliobastoma cells and is associated with poor outcomes.

“Essentially, if survivin is expressed, patients with glioblastoma have worse outcomes. So, the intent of this vaccine is to not only reverse that negative prognostic factor but on top, build efficacy [in treating the disease],” Ahluwalia said.

SurVaxM is a peptide-based vaccine that targets survivin. Survivin is a peptide which is presented the cancer cells and is not present in the normal cells. We have found survivin expression in almost all of the glioblastoma patients. It is an intracellular (located inside of a cell) protein, but it is expressed on the surface and that's why we are utilizing this peptide-based vaccine to target survivin. Survivin is an anti-apoptotic pathway (meaning a protein that inhibits cancer cell death). Essentially, if survivin is expressed, patients with glioblastoma have worse outcomes. So, the intent of this vaccine is to not only reverse that negative prognostic factor but on top, build efficacy [in treating the disease].

For more news on cancer updates, research and education, don’t forget to 

subscribe to CURE®’s newsletters here.

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells. 

Conference

In an interim analysis of a phase 2 study of Ibrance (palbociclib) researchers found the drug had a cranial benefit for patients with brain metastasis that harbored a cyclin-dependent kinases (CDK) pathway alteration, according to data presented at the 2019 Society for NeuroOncology Annual Meeting.

Ibrance is a CDK inhibitor that has shown positive results for HR-positive and HER2-negative breast cancer, but now shows promise for tackling brain metastasis that present this CDK pathway. In a genomically-guided trial, eight of the first 14 patients showed inter cranial benefit from the drug, according to Dr. Brastianos Priscilla.

Priscilla, director of the central nervous system metastasis program at Massachusetts General Hospital in Boston, had the chance to sit down with 

 and discuss the results of the phase 2 trial and what she believes this means for the future of Ibrance and treating patients with brain metastases.   

This study design was a Simon Two-Stage design where we were to enroll 15 patients to start, and if at least two patients had clinical benefit intracranially than we would proceed to the second stage of a Simon Two-Stage design. And then finally, at 30 patients, if at least six patients out of the 30 had a clinical benefit intracranially, then the treatment would be considered worthy of further study.

With the interim analysis, we were able to review the first 14 invaluable cases, and of those patients, eight patients had a clinical benefit intracranially. Which means that number one, palbociclib shows promise in this patient population of patients with brain metastases harboring CDK pathway alterations. And number two, that running a gnomically guided brain metastases trial is feasible.

New findings show that Ibrance has the potential to help patients with brain metastases that harbor a CDK pathway alteration.

Ibrance Shows Promise in Patients with Brain Metastases Who Harbor a CDK Pathway Alteration

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities at 

Hear firsthand from an Optune user and caregiver, like Steve.

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities.

Optune User Journey: Meet Steve

Olympic figure skater Scott Hamilton discusses the benefits of proton therapy.

Unlike traditional radiation, where there may be some “pass through,” proton therapy leaves little to no collateral damage by affecting tissue that is not being treated. Hamilton, who survived testicular cancer and a brain tumor, is optimistic about the future of cancer care, including immunotherapy, targeted therapy and proton therapy. In fact, after his brain tumor recurred, he asked his doctor about proton therapy and was told, “It’s an elegant option.”

One of Scott Hamilton's doctors told him that proton therapy was, "an elegant choice."

Scott Hamilton Talks Proton Therapy

The Biden Cancer Summit in Washington, DC, brought together patients, survivors, caregivers, advocates and special guests for one central purpose: make progress in the fight against cancer.

The event kicked off with a special performance by Evan Ruggiero, an osteosarcoma survivor who had his leg amputated at the age of 19. However, Ruggiero did not let the surgery stop him from pursuing his passion of dance.

Former Vice President Joe Biden also spoke to the crowd about how his and his wife's lives were changed after their son, Beau, was diagnosed with glioblastoma five years ago. Beau ended up passing away from the disease in 2015 at age 46. Watching their son go through cancer has inspired the Bidens to join in the fight against the disease, ultimately leading to the Biden Cancer Initiative -- something Mr. and Mrs. Biden are now known for around the globe.

Read more about the Biden Cancer Summit: 

https://www.curetoday.com/articles/turning-cancer-fear-into-cancer-fierce

CURE headed out to Washington, DC to cover the Biden Cancer Summit.

Finding Inspiration at the Biden Cancer Summit

Although negative results from trials evaluating immunotherapy and brain cancer were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, David Reardon, M.D., clinical director for the Center for Neuro-Oncology, Medical Oncology at the Dana-Farber Cancer Institute and associate professor of Medicine at Harvard Medical School, says that we shouldn’t write off the possibility of this treatment regimen just yet.

Brain cancers like glioblastoma (GBM) are notoriously difficult to treat, so it is going to take more research and hard work to determine how these agents can fit into the arsenal for treating GBM, he added.

Researchers should not give up hope in using immunotherapy to treat brain cancers.

Don't Write Off Immunotherapy in Brain Cancer Just Yet

When Thea Danze was four months old, she was diagnosed with a brain tumor. So, in 2011, her mother, Trisha, started a nonprofit called Thea's Star of Hope that raises funds for pediatric brain tumor research, with hopes of finding treatments that are more effective and less toxic.

 invited Trisha, Thea and Thea's younger sister, Lilly, to our video studio to learn more about the organization.

When asked about her favorite thing about Thea's Star of Hope, the ten-year-old explained that the organization is like a laser on pediatric brain tumors, shooting at them until, hopefully one day, poof! They disappear.

Raising Funds for Brain Tumors Until Poof! They Disappear

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).

When people hear about a GBM diagnosis, their first thoughts might be that there is little to no hope in treating the disease. However, recent scientific advances continue to improve outcomes for people with GBM. For example, a SurVaxM, an agent that harnesses the body’s immune system to fight the cancer, has shown promising results in trials and was granted an Orphan Drug Status by the Food and Drug Administration (FDA) in early August. Other immunotherapy agents are also in the pipeline.


David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).

Breaking Down Misconceptions About Glioblastoma

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, offers advice for patients who have recently been diagnosed with glioblastoma (GBM).

Reardon said that it is important for patients with GBM to seek out expertise in a cancer center that has a focus on GBM. Here, patients are more likely to encounter new and promising treatment strategies for the disease, many of which are in the early stages of development at large academic institutions.

Advice for Newly Diagnosed Patients With GBM

Dellann Elliott Mydland, founder and president of the EndBrainCancer Initiative and 2016 GBM Hero, discusses how miracles do happen in the world of glioblastoma multiforme (GBM), and people survive.

It is crucial to have hope when facing this type of brain tumor, and those who survive often have a top brain surgeon, have their tissue saved and get into clinical trials or new treatment quicker. Through EndBrainCancer's Direct Connect program, the organization is hoping to make this a reality for more patients.

Miracles Do Happen in GBM

I’m going to pose a question now to everyone. How can the medical team improve the care of patients with brain metastases? Perhaps we can start with having Ivy and Katie speak to that.

Patients need information. That’s probably the most important thing. When you’re diagnosed, everything is thrown at you. I think patients need to understand what brain metastasis means, how that can impact their lives, if they’re asymptomatic versus symptomatic, what the options are for treatment, both short term and possibly long term. That needs to be laid out to people in an easily understandable way up front. I also think patients need to understand what the ongoing management is going to be for brain metastases, how often they’ll be scanned, if you have certain symptoms, when you should bring that up and maybe recommend moving a scan up earlier. But basically, what it comes down to is increased information.

Brain Cancer

Latest News